Connect with us

Government

Futures Flat Ahead Of ECB And Barrage Of Bank Earnings With $2.1 Trillion In Options Expiring

Futures Flat Ahead Of ECB And Barrage Of Bank Earnings With $2.1 Trillion In Options Expiring

US index were flat on Thursday, reversing earlier…

Published

on

Futures Flat Ahead Of ECB And Barrage Of Bank Earnings With $2.1 Trillion In Options Expiring

US index were flat on Thursday, reversing earlier gains sparked by hopes of imminent easing in China, as investors turned their attention to the ECB which is set to maintain its speedier withdrawal of stimulus, data on retail sales and unemployment claims, and a barrage of earnings from Goldman Sachs, Morgan Stanley, Citigroup and Wells Fargo, and all of this happening as $2.1 trillion in options are set to expire (since tomorrow is a holiday).

At 7;00am ET, S&P futures were unchanged at 4440, Nasdaq futures were down 0.1% and Europe’s Stoxx 600 rose 0.2%. Asian stocks rose after China again indicated looser monetary policy is on the way. Treasuries extended gains as investors dialed back aggressive bets on Federal Reserve interest-rate hikes. The yen bounced from a two-decade low against the dollar. The greenback slipped after snapping its longest winning streak since 2020. Oil fell. Twitter shares soared after Elon Musk offered to buy the whole company for $54.20.

Delta Air Lines gained 0.9% in premarket trading, extending this week’s rally after it had its price projection raised at JPMorgan and Barclays. However the biggest mover in the premarket was Twitter which soared as much as 18%, and was last trading at $51 following a hostile offer by Elon Musk; Tesla shares fell.

While elevated and sticky inflation “remains a key risk for investors,” there are signs that price growth will ease in the rest of the year, according to Mark Haefele, chief investment officer at UBS Global Wealth Management. “In our base case, this should allow central banks to slow the pace of monetary tightening and tone down hawkish rhetoric,” he said. “That in turn should lower the threat of an economic hard landing.”

China is expected to cut a key policy interest rate for the second time this year on Friday and reduce the reserve requirement ratio soon. South Korea raised its key interest rate and Singapore further tightened policy, spurring advances in their currencies.

“We have actually turned cautiously optimistic on the Chinese equity market in April already,” Stefanie Holtze-Jen, Asia-Pacific chief investment officer at Deutsche Bank AG in Singapore, said on Bloomberg Television. “We perceived the communication from the government as the line in the sand.”

“We’re still being cautious” about equities, Michael Vogelzang, chief investment officer at CAPTRUST, said on Bloomberg Television. “We think there’s still a lot more that can go wrong than probably can go right.”

The latest developments over the war in Ukraine included a European Union warning for member states that President Vladimir Putin’s demand that “unfriendly countries” effectively pay for Russian gas in rubles would violate sanctions. The U.S. will expand the scope of weapons it’s providing to Ukraine in a new $800 million package of military assistance.

In Europe, gains for travel and consumer companies outweighed declines in the telecommunications and energy industries, leading the Stoxx Europe 600 Index up 0.1% and Stoxx 50 up 0.3%. CAC 40 outperforms, adding 0.4%, FTSE 100 lags, dropping 0.2%. Atlantia jumped 4.9% in Milan after the Benetton family and Blackstone offered to buy out the Italian highway operator for 23 euros per share. Ericsson dropped 5.6% in Stockholm after its earnings missed estimates. Here are some of Europe's most notable movers:

  • Wizz Air shares jump as much as 8.9% after it said it sees its 4Q operating result ahead of guidance provided at 3Q. Concorde says the low-cost carrier’s expectation to fly 30%-40% more compared with 2019 capacity in the next two quarters is “encouraging.”
  • Holcim shares rise as much as 4.3%, most since March 29, following a Bloomberg report that the group is considering the sale of assets in India.
  • Atlantia shares rise as much as 5.8% after Italy’s Benetton family and Blackstone have made a EU19b bid to buy out the infrastructure group, it follows Bloomberg News last week’s report that the firm was circled by potential suitors.
  • Hermes shares advance as much as 4.6% after publishing 1Q sales that one analyst described as “spectacular.” Peers are also up with Richemont rose as much as +3%
  • Ericsson shares fall as much as 9.2% after reporting adjusted operating profit that undershot average analyst estimates by 25%. While the first-quarter revenue came ahead of expectations, a “clear miss” on profits together with multiple new headwinds to margins may keep investors on the sidelines, according to Barclays.
  • VW shares decline as much as 2.3% after the car-maker reported preliminary figures that Jefferies says are “overall negative.”
  • UPM shares decline as much as 5.1% on Friday after the Finnish company said it has not been able to come to new collective labor agreements with the Paperworkers’ Union.
  • Ashmore shares sink as much as 9.2%, the most since April 2020, after the emerging markets-focused asset manager reported 3Q net outflows of $3.7b, which analysts say were worse than consensus expectations.

European bonds fell and the euro advanced as attention turns to the ECB, which is set to maintain its speedier withdrawal of stimulus.

Earlier in the session, Asian stocks headed for a two-day gain amid growing expectations that China’s central bank will ease policy to support growth in the region’s biggest economy. The MSCI Asia Pacific Index climbed as much as 0.8% as all sectors rose, with shares in mainland China leading the regionon hopes that the People’s Bank of China will cut its key policy rate soon. A 50-basis point, broad-based reduction in the reserve requirement ratio could also be confirmed as early as Friday, injecting 1.2 trillion yuan ($188 billion) of liquidity into the economy, Citigroup said. While an RRR cut “will help in terms of stabilizing expectations, it could be just an expedient measure as the economy urgently calls for more easing,” wrote Huatai Securities analysts including Yi Huan in a note. Asia’s cyclical and defensive shares climbed with SoftBank Group hauling up the gauge, as Mizuho Securities said the technology giant may sell some of its assets to improve its finances. 

Japan’s main gauges were also among the top performers in Asia, rising for a second day, driven by advances in technology shares. Electronics makers were the biggest boost to the Topix, which gained 1%. Fast Retailing and Tokyo Electron were the largest contributors to a 1.2% rise in the Nikkei 225.  The Kospi index ended the day little changed after the Bank of Korea raised its seven-day repurchase rate by a quarter percentage point.

China’s growth outlook has been a key pressure point for Asian shares as the country maintains its Covid Zero strategy. The MSCI Asia Pacific Index is down about 10% in 2022, extending last year’s underperformance versus the S&P 500. “China’s dynamic zero-Covid policy could ravage the Chinese economy if lockdowns continue,” Alicia Garcia Herrero, chief economist for Asia Pacific at Natixis, wrote in a note. “Beyond the reduced demand for imports from China, an even more immediate effect is inflation given the world’s dependence on China’s production of intermediate goods.”

In rates, yields are lower by as much as 2bp in 3- to 5-year sector, steepening 5s30s spread by about that much with long-end yields little changed; 10-year, lower by ~1bp at around 2.69%, outperforms bunds and gilts in the sector by 5bp-6bp. Treasuries were slightly richer across front-end and belly of the curve, steepening most curve spreads and outperforming European core rates ahead of ECB policy decision at 7:45am ET and President Christine Lagarde’s press conference. Focal points of U.S. session include retail sales data and three Fed speakers. Sifma has recommended a 2pm close ahead of Friday’s U.S. market holiday.   German curve bear-steepens with yields up 2.5-3bps across the back end. Peripheral spreads widen to Germany with 10y BTP/Bund widening 2.9bps to 242.3bps. Cash USTs bull-steepen with the curve seeing ~2bps of riching from the 5y point out. U.K. curve bear-steepens with 30y yields rising over 3bps.

The Bloomberg Dollar Spot Index headed for a second day of losses, falling 0.1%. and the dollar fell against most of its Group-of 10 peers. CHF and AUD are the weakest performers in G-10 FX, SEK and NZD outperform. The euro rose above $1.09 while yields on Bunds and Italian bonds advanced as money markets increased ECB rate hike bets ahead of the monetary policy decision.  Sweden’s krona strengthened against all of its G-10 peers and the nation’s sovereign bonds slumped, led by the front-end of the curve. Markets rushed to price in faster Riksbank tightening after its target measure, CPIF, rose to 6.1% on an annual basis in March. Economists surveyed by Bloomberg expected underlying prices to rise by 5.6%. The Australian dollar declined versus its New Zealand counterpart as the economy added fewer jobs than expected last month. Yen snapped a nine-day losing streak as U.S. yields continued to fall and players prepared for the long Easter weekend. Japanese government bonds followed Treasuries higher. BOJ Deputy Governor Masazumi Wakatabe said that it’s desirable for foreign exchange rates to reflect economic fundamentals and move in a stable manner.

In commodities, crude futures decline. WTI trades within Wednesday’s range, falling 0.7% to trade around $103. Brent falls 0.7% to $108. Most base metals trade in the red; LME zinc falls 1.1%, underperforming peers. LME aluminum outperforms, adding 1.1%. Gold weakens to around $1,972.

The commodity-fueled jump in costs exacerbated by Russia’s war in Ukraine continues to ripple across the global economy and color market sentiment. JPMorgan Chase & Co. Chief Executive Officer Jamie Dimon said inflation and the conflict were creating “significant” challenges. The firm was among the first of the big U.S. banks to report earnings.

Looking to the day ahead, the main highlight will be the ECB’s latest policy decision. We’ll also hear from the Fed’s Williams, Mester and Harker. Data releases include US retail sales for March, the weekly initial jobless claims, and the University of Michigan’s preliminary consumer sentiment index for April. Lastly, earnings releases are again financials heavy, with Wells Fargo, Citigroup, Morgan Stanley, Goldman Sachs and UnitedHealth Group showcasing.

Market Snapshot

  • S&P 500 futures down 0.1% to 4,437.75
  • STOXX Europe 600 little changed at 457.19
  • MXAP up 0.6% to 175.12
  • MXAPJ up 0.4% to 580.08
  • Nikkei up 1.2% to 27,172.00
  • Topix up 1.0% to 1,908.05
  • Hang Seng Index up 0.7% to 21,518.08
  • Shanghai Composite up 1.2% to 3,225.64
  • Sensex down 0.4% to 58,338.93
  • Australia S&P/ASX 200 up 0.6% to 7,523.43
  • Kospi little changed at 2,716.71
  • German 10Y yield little changed at 0.78%
  • Euro up 0.2% to $1.0906
  • Brent Futures down 0.7% to $108.07/bbl
  • Gold spot down 0.1% to $1,975.23
  • U.S. Dollar Index down 0.17% to 99.71

Top Overnight News from Bloomberg

  • Jumbo-sized interest rate hikes from Canada to New Zealand are boosting market confidence that central banks are on track to tame inflation, putting bonds back in investors’ focus
  • Russian authorities are considering a step-by-step approach to rolling back the harsh capital controls imposed to stabilize markets after the invasion of Ukraine. Discussions this week focused on options that included extending the deadline for exporters to carry out mandatory conversions of their overseas earnings into rubles and lowering below 80% the share of foreign proceeds that companies are obliged to sell in the market, according to people informed on the matter
  • Russia threatened to deploy nuclear weapons in and around the Baltic Sea region if Finland and Sweden join the North Atlantic Treaty Organization as tensions fueled by Vladimir Putin’s invasion of Ukraine spread
  • Singapore’s central bank further tightened monetary settings and raised its inflation forecast, sending the currency higher as it seeks to fight cost pressures that threaten the recovery from the pandemic
  • Chinese President Xi Jinping says his government will stick to its zero-tolerance approach to Covid even as public anger simmers in Shanghai and economic costs mount
  • Copper and aluminum rose on signs China will loosen monetary policy to revive its virus-wracked economy, while zinc dipped but remained near the highest close since 2006 amid a global supply crunch

A More detailed breakdown of global news from Newsquawk

Asia-Pac stocks were mostly positive after the gains on Wall St where risk appetite was supported by lower yields, although some bourses lagged on policy tightening. ASX 200 traded higher but with gains capped by cautiousness in the top-weighted financials sector after Bank of Queensland's shares failed to benefit post-earnings. Nikkei 225 outperformed and reclaimed the 27,000 level with Japan's ruling coalition parties unveiling their draft relief proposals. Fast Retailing (9983 JT) 6-month (JPY): Net Profit 146.84bln, +38.7%; Operating Profit 189.3bln, +12.7%; Pretax Profit 212.6bln, +24%; Sees FY net income at 190bln (prev. guidance 175bln). KOSPI and Straits Times Index lagged after the BoK unexpectedly hiked rates by 25bps points and the MAS tightened FX-based policy, respectively. Hang Seng and Shanghai Comp were kept afloat with speculation rife that the PBoC will lower rates tomorrow via an MLF rate cut, while Citi also sees the possibility for a RRR cut on Friday to free up around CNY 1.2tln cash.

Top Asian News

  • Chinese Stocks Advance as Key Rate Cut Seen as Soon as Friday
  • TSMC Raises Sales Outlook Despite Fears Around Global Demand
  • Sri Lanka Seeking Up to $4 Billion as IMF Talks Set to Start
  • Uniqlo Owner Gets Serious About Conquering North American Market

European bourses are firmer, Euro Stoxx 50 +0.4%, but off best levels as sentiment was hit on commentary from Russia's  Medvedev and as we await key bank earnings. Sectors in Europe are contained and are not exhibiting any pronounced theme thus far. US futures remain within narrow parameters at this point in time awaiting updates from Goldman Sachs and Morgan Stanley before Retail Sales rounds off the week's key data; NQ +0.1%. Tesla (TSLA) CEO Musk, on April 13th, offered to purchase all of the outstanding Twitter (TWTR) shares for USD 54.20/shr (vs prior close of USD 45.85); said it was his final offer. TWTR +13% in the pre-market. TSMC (2330 TW) Q1 (TWD): Revenue 491bln (prev. 362bln), Net Profit 202.7bln (exp. 184.7bln), Gross Margin 55.6%. Expects chip demand to continue in the long term, believes capacity will remain tight this year and expects another strong year. Working to address supply chain challenges with tool suppliers.

Top European News

  • ArcelorMittal Buys $1 Billion Voestalpine Plant in Texas
  • VW Sees Profit Surge on $3.8 Billion Hedging Boost
  • Valneva’s Covid Vaccine Gets U.K. Clearance After Rocky Ride
  • Macron’s Lead Grows in French Election Polling Average

FX:

  • DXY almost full point down from midweek y-t-d peak as US Treasury yields continue to recede ahead of packed pre-Easter agenda index hovering above 95.500 vs 100.520 high.
  • Kiwi rebounds after RBNZ letdown with tailwinds from AUD/NZD cross in wake of weaker than forecast Aussie jobs data, NZD/USD back on 0.6800 handle, AUD/USD straddling 0.7450.
  • Euro takes advantage of Greenback retreat awaiting words of wisdom from ECB President Lagarde following policy announcement that is not expected to reveal changes; EUR/USD above 1.0900 vs close shave with 2022 low (1.0806) yesterday.
  • Swedish Crown aloft as more consensus and Riksbank target topping inflation prints prompt earlier rate hike calls, EUR/SEK pivots 10.3000.
  • Korean Won and Singapore Dollar boosted by shock BoK hike and MAS tightening, but Chinese Yuan backs off amidst growing speculation about PBoC easing possibly as soon as tomorrow.

Fixed income:

  • Eurozone bonds extend retreat from recovery peaks and underperformance ahead of the ECB.
  • Bunds nearer 155.00 after rebound to just shy of 156.00, Gilts sub-119.00 vs 119.65 Liffe high and 10 year T-note closer to 120-19+ overnight bottom than 121-05+ top.
  • US Treasuries down in sympathy with Gilts and curve a tad steeper after so-so long bond auction.
  • Debt also defensive pre-long Easter weekend and busy line up of US data, including IJC and retail sales.

Commodities:

  • WTI and Brent are pressured and in relatively proximity to the session's troughs of USD 102.50/bbl and USD 107.01/bbl.
  • Newsflow remains focused on Ukraine-Russia, particularly Medvedev's commentary, and the COVID situation in China as other cities are on edge re. Shanghai.
  • Libyan National Unity Government adopted a plan to develop the oil sector to raise output to 1.4mln bpd, according to Reuters.
  • Chinese refiners are seen cutting April's crude throughput by 900k BPD, around 6% of the 2021 average, via Reuters citing sources/analysts; expected to export 2mln/T of refined fuel in April, counter to earlier China plan to halt exports.
  • Spot gold/silver are pressured and have lost the brief upside derived from earlier geopolitical developments, yellow metal at lows of USD 1967/oz.

US Event Calendar

  • 08:30: April Initial Jobless Claims, est. 170,000, prior 166,000
    • Continuing Claims, est. 1.5m, prior 1.52m
  • 08:30: March Import Price Index YoY, est. 11.9%, prior 10.9%; MoM, est. 2.3%, prior 1.4%
    • March Export Price Index YoY, est. 16.2%, prior 16.6%; MoM, est. 2.2%, prior 3.0%
  • 08:30: March Retail Sales Advance MoM, est. 0.6%, prior 0.3%
    • March Retail Sales Ex Auto MoM, est. 1.0%, prior 0.2%
    • March Retail Sales Control Group, est. 0.1%, prior -1.2%
  • 10:00: Feb. Business Inventories, est. 1.3%, prior 1.1%
  • 10:00: April U. of Mich. Sentiment, est. 59.0, prior 59.4;
    • Current Conditions, est. 67.0, prior 67.2
    • Expectations, est. 53.6, prior 54.3
    • 1 Yr Inflation, est. 5.5%, prior 5.4%;  5-10 Yr Inflation, prior 3.0%

DB concludes the overnight wrap

The EMR will be joining much of the market on holiday and will be back on Tuesday. A happy, restful long weekend to our loyal readers, and cheers to whatever it is you may be celebrating.

Ahead of the holiday, the yield curve rose on the third day straight, with 2s10s having risen +42.5bps since its nadir at the start of the month. Global sovereign yields modestly fell, while US equities outperformed their European counterparts. The ECB meets today, where our economists are not expecting a change in tune.

Starting with Ukraine, the US announced another round of aid, which will include heavy weaponry. Meanwhile, Finland has started the process to obtain NATO membership, and Swedish media report Sweden is considering the same. This, following President Biden labelling Russia’s excursions into Ukraine a genocide, the lack of negotiation progress, and the collective bracing for a renewed assault in the east, has cast a gloomy pall over the conflict. The International Energy Agency elsewhere warned that the disruption to Russian oil supply has yet to bind, with upwards of 3m bbls/day coming offline starting in May. The combined effect was to send Brent crude oil futures higher, which gained +4.14% yesterday to $108.78bbl, their highest level in two weeks following a +10.5% gain over the last two days.

Sovereign yields had a subdued day by the standards of recent volatility, with yields falling across most jurisdictions and tenors. 10yr Treasuries were down -2.3bps, outpaced by the -5.7bp decline in 2yr yields that led to a further steepening of the curve. Most of the declines came in the New York morning, when reports of large block futures trades were relentlessly hitting the tapes.

In Europe, 10yr bund, OAT, and BTP yields were -2.4bps, -3.5bps, and -3.4bps lower ahead of today’s ECB meeting, respectively. Both ECB meetings so far this year have surprised on the hawkish side of expectations, which comes as inflation has continued to accelerate to the fastest since the single currency’s formation, at +7.5% in March. Today, however, our economists preview (link here) that they’re not expecting much change to the ECB’s message. Instead, they believe with the new staff forecasts in June, the ECB will announce that APP purchases will end in July, ahead of liftoff in September.

Equities were mixed in Europe, with the DAX falling -0.34%, while the STOXX 600 and CAC managed marginal gains of +0.03% and +0.07%, respectively. Farther from the conflict, the S&P 500 outperformed, climbing +1.12%, with mega-cap shares leading the way on falling discount rates, as the FANG+ climbed +2.06%. The S&P outperformance came amidst mixed results from some bellwether US financials, with JPM missing analyst earnings expectations while Blackrock sales came below expectations. In their release, JPM noted that they were increasing reserves to account for increased recession probabilities and to account for exposures to the war, two themes likely to suffuse earnings releases this season.

In other central bank news, the Bank of Canada rose rates by +50bps to 1.00%, as was expected, and announced that their bond purchases would stop on April 25, a decision that contained some intrigue. The 50bp hike was the largest since 2000; Canada is no outlier in fighting multi-decade high inflation. The BoC said interest rates would need to rise further, as there was growing risk of higher inflation expectations becoming entrenched, a primal fear for any central banker. How much further? President Macklem suggested rates may need to surpass neutral if inflation doesn’t moderate, and the BoC happened to revise their neutral rate 25bps higher to a range between 2% and 3%. They also revised higher their inflation and GDP forecasts for 2022, revising down their 2023 growth forecast to 3.2%, which is nevertheless still above trend growth.

US producer prices grew at a much faster rate than analysts were expecting, with final demand growing +11.2% year-on-year, versus expectations of +10.6%, while the core measure grew at +9.2%. Interesting enough, the elements of PPI that feed into core PCE were among those that printed to the soft side. Combined with the CPI data from the day before, our economists are expecting core PCE in March to grow at +0.25%

Asian equity markets are following US stocks higher this morning, with most indices in the green, augmented by China signalling a potential impending RRR cut. US equity futures are pointing to a steady start today, with contracts on the S&P 500 (+0.07%) and Nasdaq 100 (+0.16%) both a smidge higher. Brent crude futures are -0.61% down to $108.12/bbl. 10yr Treasury yields have declined -2.7bps to 2.67%, with the 2yr yields edging -2.9bps lower to 2.32%.

The Bank of Korea got in on the global tightening overnight, lifting its base rate by +25bps to 1.5%, its highest since August 2019 and making it the fourth rate increase since August 2021. The increase came even without the formal appointment of a new governor Rhee Chang-yong, who is expected to begin his four-year term from April 19.

With 10 days left until the French Presidential election, polls show a consistent lead for President Macron. His lead over Marine Le Pen expanded in 3 of the 4 polls released yesterday, yet still reflect a smaller expected margin of victory than his previous triumph. The spread of French 10yr yields over bunds narrowed to close beneath 50bps for the first time in over a week.

Aside from the US PPI data, the other main release yesterday were the UK inflation numbers, where the year-on-year measure for headline CPI rose to +7.0% (vs. +6.7% expected). That’s the 6th consecutive month that the reading has surpassed the consensus expectation, whilst core CPI also surprised to the upside at +5.7% (vs. +5.3% expected). In turn, investors moved to raise the probability of a 50bp hike in May from the Bank of England to 28%, the highest in a couple of weeks. Our UK economist also put out an update after the report (link here) move above 9% year-on-year in the April data next month.

To the day ahead now, the main highlight will be the ECB’s latest policy decision. We’ll also hear from the Fed’s Williams, Mester and Harker. Data releases include US retail sales for March, the weekly initial jobless claims, and the University of Michigan’s preliminary consumer sentiment index for April. Lastly, earnings releases are again financials heavy, with Wells Fargo, Citigroup, Morgan Stanley, Goldman Sachs and UnitedHealth Group showcasing.

Tyler Durden Thu, 04/14/2022 - 07:25

Read More

Continue Reading

International

Who Can You Trust?

Who Can You Trust?

Authored by James Howard Kunstler via Kunstler.com,

“I’m sick and tired of hearing Democrats whining about Joe Biden’s…

Published

on

Who Can You Trust?

Authored by James Howard Kunstler via Kunstler.com,

“I’m sick and tired of hearing Democrats whining about Joe Biden’s age. The man knows how to govern. Just shut up and vote to save Democracy.”

- Rob Reiner, Hollywood savant

Perhaps you’re aware that the World Health Organization (WHO) is cooking up a plan to impose its will over all the sovereign nations on this planet in the event of future pandemics.

That means, for instance, that the WHO would issue orders to the USA about lockdowns, vaccines, and vaccine passports and we US citizens supposedly would be compelled to follow them.

Why the “Joe Biden” regime would go along with this globalist fuckery is one of the abiding mysteries of our time - except that they go along with everything else that the cabal of Geneva cooks up, such as attacks on farmers, and on oil production, and on relations between men and women, and on personal privacy, and on economic liberty throughout Western Civ, as if they’re working overtime to kill it off. And all of us with it.

I think they are working overtime at that because the sore-beset citizens of Western Civ are onto their game, and getting restless about it. So, the Geneva cabal is in a race against time before the center pole of their circus tent collapses and the nations of the world are compelled to follow the zeitgeist in the direction of de-centralizing, foiling all their grand plans.

The “Joe Biden” regime is pretending to ignore the reality that this WHO deal is actually a treaty that would require ratification by a two-thirds vote in the senate, an unlikely outcome. In any case, handing over authority to the WHO — in effect, to its chief Tedros Adhanom Ghebreyesus — to push around American citizens like a giant herd of cattle would be patently unlawful.

That center pole of the circus tent is the wobbling global economy. It’s barely holding up the canvas over the three rings of the circus. In the center ring, the death-defying spectacle of the Biden Family crime case is playing out before a huge audience (us). This week, a gun went off at the FBI and smoke is curling out of the barrel. FBI Director Christopher Wray was forced to verify that he’s been sitting on an incriminating document for three years from a “trusted” confidential human source, i.e., an informant, stating that the Biden Family received a $5-million bribe from a foreign entity when “JB” was vice-president.

That’s only one bribe of many others, of course, as documented in the Hunter Biden laptop, and it must be obvious it represents treasonous behavior that will demand resignation or impeachment. As this spools out in the weeks and months ahead, do you think Americans will be in the mood to accept further insults such as “Joe Biden” surrendering our national sovereignty to the WHO?

Anyway, you must ask yourself: why on earth should I trust the WHO about anything? Did they not participate in laying a trip on the world with Covid-19? How did those lockdowns work out? Do you think they destroyed enough businesses and ruined enough households? How’s the vaccination program doing? Effective? Safe? Yeah, maybe not so much. Maybe killing a lot of people, wrecking immune systems, sterilizing reproductive organs, causing gross disabilities, shattering lives.

Of course, in over three years neither the WHO nor the US medical authorities showed the slightest interest in helping to figure out how the Covid-19 virus was made in a lab, and exactly how it got loose in the world. Lately, Dr. Ghebreyesus has warned the world about much worse future pandemics supposedly coming down at us. Oh? Really? What does he know that we don’t? That possibly new efforts to concoct chimeric diseases are ongoing in labs around the world? (You know that dozens of such labs were discovered in Ukraine as the war got underway there in 2022.) What’s Dr. Ghebreyesus doing to stop that?

If US orgs and citizens are involved in this “research,” why doesn’t the WHO alert our government leaders so they can stop it? (Would they? I’m not so sure.) And, who is behind it this time? The Eco-Health Alliance again, like with Covid-19? By the way, that outfit got another whopping grant last fall from the NIH to “study” bat viruses — right after the NIH terminated a previous grant on account of The Eco-Health Alliance failing to turn over notebooks and other records.

No, you cannot trust the WHO about anything. The “trust horizon” (a concept introduced by the great Nicole Foss, late of The Automatic Earth dot com) is shrinking. You can no longer trust any distant authorities. You also cannot trust the US federal government (especially the executive branch behind “Joe Biden”). And notice: the trust horizon is shrinking just as the world is de-centralizing. This, you see, is the main contradiction behind all the Globalists’ twisted ambitions to control everything, including you. They are working against the current tide of human history which is pushing everything toward down-scaling, re-localization, and re-assertion of the sovereign individual person.

That trend will become increasingly evident as things organized at the giant scale start to implode — giant retail chains, medical behemoths, hedge funds, big banks, you name it. The world no longer has the mojo for globalism. There’s reason to wonder these days whether the USA has the mojo to remain a unified national polity of states. Our federal government is not only financially bankrupt beyond any coherent reckoning, it is also morally bankrupt, and it has decided to make war against its own people. None of this is satisfactory and none of this is working. It’s time to figure out who and what you can trust and act accordingly.

Tyler Durden Sun, 06/04/2023 - 09:20

Read More

Continue Reading

Spread & Containment

Removing antimicrobial resistance from the WHO’s ‘pandemic treaty’ will leave humanity extremely vulnerable to future pandemics

Drug-resistant microbes are a serious threat for future pandemics, but the new draft of the WHO’s international pandemic agreement may not include provisions…

Published

on

By

Antimicrobial resistance is now a leading cause of death worldwide due to drug-resistant infections, including drug-resistant strains of tuberculosis, pneumonia and Staph infections like the methicillin-resistant Staphylococcus aureus shown here. (NIAID, cropped from original), CC BY

In late May, the latest version of the draft Pandemic Instrument, also referred to as the “pandemic treaty,” was shared with Member States at the World Health Assembly. The text was made available online via Health Policy Watch and it quickly became apparent that all mentions of addressing antimicrobial resistance in the Pandemic Instrument were at risk of removal.

Work on the Pandemic Instrument began in December 2021 after the World Health Assembly agreed to a global process to draft and negotiate an international instrument — under the Constitution of the World Health Organization (WHO) — to protect nations and communities from future pandemic emergencies.


Read more: Drug-resistant superbugs: A global threat intensified by the fight against coronavirus


Since the beginning of negotiations on the Pandemic Instrument, there have been calls from civil society and leading experts, including the Global Leaders Group on Antimicrobial Resistance, to include the so-called “silent” pandemic of antimicrobial resistance in the instrument.

Just three years after the onset of a global pandemic, it is understandable why Member States negotiating the Pandemic Instrument have focused on preventing pandemics that resemble COVID-19. But not all pandemics in the past have been caused by viruses and not all pandemics in the future will be caused by viruses. Devastating past pandemics of bacterial diseases have included plague and cholera. The next pandemic could be caused by bacteria or other microbes.

Antimicrobial resistance

Yellow particles on purple spikes
Microscopic view of Yersinia pestis, the bacteria that cause bubonic plague, on a flea. Plague is an example of previous devastating pandemics of bacterial disease. (NIAID), CC BY

Antimicrobial resistance (AMR) is the process by which infections caused by microbes become resistant to the medicines developed to treat them. Microbes include bacteria, fungi, viruses and parasites. Bacterial infections alone cause one in eight deaths globally.

AMR is fueling the rise of drug-resistant infections, including drug-resistant tuberculosis, drug-resistant pneumonia and drug-resistant Staph infections such as methicillin-resistant Staphylococcus aureus (MRSA). These infections are killing and debilitating millions of people annually, and AMR is now a leading cause of death worldwide.

Without knowing what the next pandemic will be, the “pandemic treaty” must plan, prepare and develop effective tools to respond to a wider range of pandemic threats, not solely viruses.

Even if the world faces another viral pandemic, secondary bacterial infections will be a serious issue. During the COVID-19 pandemic for instance, large percentages of those hospitalized with COVID-19 required treatment for secondary bacterial infections.

New research from Northwestern University suggests that many of the deaths among hospitalized COVID-19 patients were associated with pneumonia — a secondary bacterial infection that must be treated with antibiotics.

An illustrative diagram that shows the difference between a drug resistant bacteria and a non-resistant bacteria.
Antimicrobial resistance means infections that were once treatable are much more difficult to treat. (NIAID), CC BY

Treating these bacterial infections requires effective antibiotics, and with AMR increasing, effective antibiotics are becoming a scarce resource. Essentially, safeguarding the remaining effective antibiotics we have is critical to responding to any pandemic.

That’s why the potential removal of measures that would help mitigate AMR and better safeguard antimicrobial effectiveness is so concerning. Sections of the text which may be removed include measures to prevent infections (caused by bacteria, viruses and other microbes), such as:

  • better access to safe water, sanitation and hygiene;
  • higher standards of infection prevention and control;
  • integrated surveillance of infectious disease threats from human, animals and the environment; and
  • strengthening antimicrobial stewardship efforts to optimize how antimicrobial drugs are used and prevent the development of AMR.

The exclusion of these measures would hinder efforts to protect people from future pandemics, and appears to be part of a broader shift to water-down the language in the Pandemic Instrument, making it easier for countries to opt-out of taking recommended actions to prevent future pandemics.

Making the ‘pandemic treaty’ more robust

Measures to address AMR could be easily included and addressed in the “pandemic treaty.”

In September 2022, I was part of a group of civil society and research organizations that specialize in mitigating AMR who were invited the WHO’s Intergovernmental Negotiating Body (INB) to provide an analysis on how AMR should be addressed, within the then-draft text.

They outlined that including bacterial pathogens in the definition of “pandemics” was critical. They also identified specific provisions that should be tweaked to track and address both viral and bacterial threats. These included AMR and recommended harmonizing national AMR stewardship rules.

In March 2023, I joined other leading academic researchers and experts from various fields in publishing a special edition of the Journal of Medicine, Law and Ethics, outlining why the Pandemic Instrument must address AMR.

The researchers of this special issue argued that the Pandemic Instrument was overly focused on viral threats and ignored AMR and bacterial threats, including the need to manage antibiotics as a common-pool resource and revitalize research and development of novel antimicrobial drugs.

Next steps

While earlier drafts of the Pandemic Instrument drew on guidance from AMR policy researchers and civil society organizations, after the first round of closed-door negotiations by Member States, all of these insertions, are now at risk for removal.

The Pandemic Instrument is the best option to mitigate AMR and safeguard lifesaving antimicrobials to treat secondary infections in pandemics. AMR exceeds the capacity of any single country or sector to solve. Global political action is needed to ensure the international community works together to collectively mitigate AMR and support the conservation, development and equitable distribution of safe and effective antimicrobials.

By missing this opportunity to address AMR and safeguard antimicrobials in the Pandemic Instrument, we severely undermine the broader goals of the instrument: to protect nations and communities from future pandemic emergencies.

It is important going forward that Member States recognize the core infrastructural role that antimicrobials play in pandemic response and strengthen, rather than weaken, measures meant to safeguard antimicrobials.

Antimicrobials are an essential resource for responding to pandemic emergencies that must be protected. If governments are serious about pandemic preparedness, they must support bold measures to conserve the effectiveness of antimicrobials within the Pandemic Instrument.

Susan Rogers Van Katwyk is a member of the WHO Collaborating Centre on Global Governance of Antimicrobial Resistance at York University. She receives funding from the Wellcome Trust and the Social Sciences and Humanities Research Council of Canada.

Read More

Continue Reading

Spread & Containment

Repeated COVID-19 Vaccination Weakens Immune System: Study

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19…

Published

on

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.

A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. (Joseph Prezioso/AFP via Getty Images)

Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.

They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.

Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.

A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.

“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.

The paper was published by the journal Vaccines in May.

Pfizer and Moderna officials didn’t respond to requests for comment.

Both companies utilize messenger RNA (mRNA) technology in their vaccines.

Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.

“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.

So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”

Possible Problems

The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.

Read more here...

Tyler Durden Sat, 06/03/2023 - 22:30

Read More

Continue Reading

Trending